Loading...
•
Dec 31, 2022
Dynavax Q4 2022 Earnings Report
Reported financial results for the fourth quarter and full year ending December 2022.
Key Takeaways
Dynavax reported a decrease in total revenue for the fourth quarter of 2022, with $184.5 million compared to $195.1 million for the fourth quarter of 2021. However, HEPLISAV-B vaccine product revenue increased to $34.9 million from $17.2 million in the same period.
Total revenue for Q4 2022 was $184.5 million, compared to $195.1 million for Q4 2021.
HEPLISAV-B vaccine product revenue for Q4 2022 was $34.9 million, compared to $17.2 million for Q4 2021.
CpG 1018 adjuvant product revenue for Q4 2022 was $147.2 million, compared to $177.4 million for Q4 2021.
GAAP net income was $67.7 million, or $0.53 per share (basic) and $0.45 per share (diluted) in Q4 2022, compared to $99.8 million in Q4 2021.
Forward Guidance
Dynavax anticipates full-year 2023 revenue and operating expenses to be in the ranges below:
Positive Outlook
- HEPLISAV-B net product revenue between approximately $165 - $185 million
Challenges Ahead
- Research and development expenses between approximately $55 - $70 million
- Selling, general and administrative expenses between approximately $135 - $155 million
- minimal to as little as zero CpG 1018 adjuvant net product revenues in 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...